ProMIS Posts Q3 2026 Results; $44.1M Cash Funds Operations Through 2027
PMN sits 25% above its 52-week low of $2.78.
Summary
ProMIS reported a Q3 2026 net loss of $8.2 million and $44.1 million of cash, enough to fund operations through 2027 — beyond the Q1 2027 PRECISE-AD topline data readout it reaffirmed today.
Key Events · Earnings and Guidance · PMN
-
Q3 Loss Narrows to $8.2M
Net loss was $8.2 million, or $(0.89) per share, versus $11.6 million, or $(5.93) per share, a year earlier; R&D fell 32% to $6.7 million as PRECISE-AD patient visits wound down.
-
Cash of $44.1M Funds Through 2027
Cash stood at $44.1 million at September 30, 2026, up from $6.1 million at December 31, 2025 on $70.1 million of January private-placement net proceeds — runway past the Q1 2027 topline readout.
-
PRECISE-AD Topline Reaffirmed for Q1 2027
Unblinded 12-month safety, biomarker and cognitive data remain on track for Q1 2027, with all patient visits expected to complete in Q4 2026.
-
Chief Commercial Officer Appointed
Ivana Rubino, Ph.D., a former Biogen and Roche neuroscience executive, joined as Chief Commercial Officer effective October 5, 2026.
Analysis · PMN · Life Sciences
The quarter itself is unremarkable: a $8.2 million net loss, down from $11.6 million a year ago, on R&D that fell 32% to $6.7 million as PRECISE-AD wound down patient visits. The balance sheet is what matters. Cash of $44.1 million at September 30, up from $6.1 million at year-end on $70.1 million of January private-placement proceeds, funds operations through 2027 by management's account — past the Q1 2027 unblinded 12-month PRECISE-AD topline readout. That removes any near-term financing overhang ahead of the binary Alzheimer's data event. And the hiring of a Chief Commercial Officer from Biogen and Roche signals the company is staffing for a commercial path rather than a sale.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMN was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2M. The 52-week trading range was $2.78 to $27.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.